JP2016529315A5 - - Google Patents

Download PDF

Info

Publication number
JP2016529315A5
JP2016529315A5 JP2016540405A JP2016540405A JP2016529315A5 JP 2016529315 A5 JP2016529315 A5 JP 2016529315A5 JP 2016540405 A JP2016540405 A JP 2016540405A JP 2016540405 A JP2016540405 A JP 2016540405A JP 2016529315 A5 JP2016529315 A5 JP 2016529315A5
Authority
JP
Japan
Prior art keywords
hydrocarbyl
pharmaceutical composition
halo
optionally substituted
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016540405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529315A (ja
JP6472450B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/054209 external-priority patent/WO2015035117A1/en
Publication of JP2016529315A publication Critical patent/JP2016529315A/ja
Publication of JP2016529315A5 publication Critical patent/JP2016529315A5/ja
Application granted granted Critical
Publication of JP6472450B2 publication Critical patent/JP6472450B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016540405A 2013-09-06 2014-09-05 ピラゾロ[1,5−a]ピリミジン系化合物、それを含む組成物、及びそれらの使用方法 Active JP6472450B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361874395P 2013-09-06 2013-09-06
US61/874,395 2013-09-06
PCT/US2014/054209 WO2015035117A1 (en) 2013-09-06 2014-09-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Publications (3)

Publication Number Publication Date
JP2016529315A JP2016529315A (ja) 2016-09-23
JP2016529315A5 true JP2016529315A5 (enExample) 2017-10-05
JP6472450B2 JP6472450B2 (ja) 2019-02-20

Family

ID=51542502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540405A Active JP6472450B2 (ja) 2013-09-06 2014-09-05 ピラゾロ[1,5−a]ピリミジン系化合物、それを含む組成物、及びそれらの使用方法

Country Status (12)

Country Link
US (2) US20150175610A1 (enExample)
EP (1) EP3041475B1 (enExample)
JP (1) JP6472450B2 (enExample)
CN (1) CN105517553B (enExample)
AR (1) AR097545A1 (enExample)
AU (1) AU2014315113B2 (enExample)
CA (1) CA2923317C (enExample)
DK (1) DK3041475T3 (enExample)
ES (1) ES3009382T3 (enExample)
PT (1) PT3041475T (enExample)
TW (1) TW201542550A (enExample)
WO (1) WO2015035117A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6473146B2 (ja) 2013-10-11 2019-02-20 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ピロロトリアジンキナーゼ阻害剤
HRP20240644T1 (hr) 2014-11-06 2024-08-02 Bial-R&D Investments, S.A. Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
CA2966581A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
SG11201808830YA (en) 2016-04-06 2018-11-29 Lysosomal Therapeutics Inc Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
JP7046827B2 (ja) 2016-04-06 2022-04-04 リソソーマル・セラピューティクス・インコーポレイテッド イミダゾ[1,5-a]ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
US11124516B2 (en) 2016-04-06 2021-09-21 BIAL-BioTech Investments, Inc. Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
JP7164774B2 (ja) 2016-05-05 2022-11-02 ビアル-アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ 置換イミダゾ[1,2-b]ピリダジン、置換イミダゾ[1,5-b]ピリダジン、関連化合物、および医学的障害の治療におけるその使用
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US11414431B2 (en) * 2018-10-15 2022-08-16 Nimbus Lakshmi, Inc. Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US7662826B2 (en) * 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
ATE460417T1 (de) * 2005-03-23 2010-03-15 Hoffmann La Roche Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
ES2340321T3 (es) 2005-09-27 2010-06-01 F.Hoffmann-La Roche Ag Oxadiazolilpirazolo-pirimidinas, como antagonistas de mglur2.
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ[1,5−a]ピリミジン化合物
WO2008045664A2 (en) * 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
JP2010508315A (ja) * 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
EA019507B1 (ru) * 2008-05-13 2014-04-30 Айрм Ллк Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
PT3106463T (pt) * 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
AU2010249493A1 (en) 2009-05-20 2011-12-08 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as kinase inhibitors
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011073316A1 (en) * 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
WO2011087999A1 (en) * 2010-01-14 2011-07-21 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
KR101953210B1 (ko) * 2011-05-19 2019-02-28 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ 단백질 키나아제 억제제로서의 대환식 화합물
HUE036040T2 (hu) 2012-03-09 2018-06-28 Lexicon Pharmaceuticals Inc Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére
CN104302649B (zh) * 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof

Similar Documents

Publication Publication Date Title
JP2015509535A5 (enExample)
JP2016529315A5 (enExample)
JP2016529319A5 (enExample)
JP2015509534A5 (enExample)
JP2013537203A5 (enExample)
JP2016540742A5 (enExample)
JP2017504635A5 (enExample)
JP2016530259A5 (enExample)
JP2015537020A5 (enExample)
JP2013010792A5 (enExample)
JP2016514159A5 (enExample)
JP2012513416A5 (enExample)
JP2019524883A5 (enExample)
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
JP2017511321A5 (enExample)
JP2015500843A5 (enExample)
JP2016500661A5 (enExample)
JP2018531941A5 (enExample)
JP2017514910A5 (enExample)
JP2016505614A5 (enExample)
JP2013542261A5 (enExample)
JP2016519165A5 (enExample)
JP2019501130A5 (enExample)
JP2015535847A5 (enExample)
JP2015051983A5 (enExample)